Evidence map›Paper›PMID 35082400›Full record

ReviewCancer gene therapy2022

Mesenchymal stem cell (MSC)-derived exosomes as novel vehicles for delivery of miRNAs in cancer therapy.

Behnoush Sohrabi, Behnaz Dayeri, Elahe Zahedi, Shahrouz Khoshbakht, Najme Nezamabadi Pour, Hamta Ranjbar, Abolfazl Davari Nejad, Mahdi Noureddini, Behrang Alani

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer gene therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Behnoush SohrabiDepartment of Biology, Faculty of Sciences, Arak University, Arak, Iran.
Behnaz DayeriFaculty of Medicine, Dezful University of Medical Sciences, Dezful, Iran.
Elahe ZahediDepartment of Chemical Engineering, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Shahrouz KhoshbakhtStudent Research Committee, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
Najme Nezamabadi PourDepartment of Pediatrics, School of Medicine, Bam University of Medical Sciences, Bam, Iran.
Hamta RanjbarStudent Research Committee, Kerman University of Medical Sciences, Kerman, Iran.
Abolfazl Davari NejadStudent Research Committee, Kerman University of Medical Sciences, Kerman, Iran.
Mahdi NoureddiniPhysiology Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Behrang AlaniDepartment of Applied Cell Sciences, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran. Alani-be@kaums.ac.ir.ORCID http://orcid.org/0000-0003-0506-5703
Kashan University of Medical Sciences · IRKerman University of Medical Sciences · IRArak University · IRBam University of Medical Sciences · IRDezful University of Medical Sciences · IRIslamic Azad University North Tehran Branch · IRUniversity of Social Welfare and Rehabilitation Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) are known as promising sources for cancer therapy and can be utilized as vehicles in cancer gene therapy. MSC-derived exosomes are central mediators in the therapeutic functions of MSCs, known as the novel cell-free alternatives to MSC-based cell therapy. MSC-derived exosomes show advantages including higher safety as well as more stability and convenience for storage, transport and administration compared to MSCs transplant therapy. Unmodified MSC-derived exosomes can promote or inhibit tumors while modified MSC-derived exosomes are involved in the suppression of cancer development and progression via the delivery of several therapeutics molecules including chemotherapeutic drugs, miRNAs, anti-miRNAs, specific siRNAs, and suicide gene mRNAs. In most malignancies, dysregulation of miRNAs not only occurs as a consequence of cancer progression but also is directly involved during tumor initiation and development due to their roles as oncogenes (oncomiRs) or tumor suppressors (TS-miRNAs). MiRNA restoration is usually achieved by overexpression of TS-miRNAs using synthetic miRNA mimics and viral vectors or even downregulation of oncomiRs using anti-miRNAs. Similar to other therapeutic molecules, the efficacy of miRNAs restoration in cancer therapy depends on the effectiveness of the delivery system. In the present review, we first provided an overview of the properties and potentials of MSCs in cancer therapy as well as the application of MSC-derived exosomes in cancer therapy. Finally, we specifically focused on harnessing the MSC-derived exosomes for the aim of miRNA delivery in cancer therapy.

Indexed as

ExosomesMesenchymal Stem CellsMicroRNAsNeoplasmsCell- and Tissue-Based TherapyHumansMicroRNAs

Identifiers

PMID35082400
OpenAlexW4224242310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.